2024年11月28日，上海交通大学-曼彻斯特大学工商管理博士（SJTU-UoM DBA）2017级学生徐应永同学以优异的成绩（A2等级）顺利通过了论文答辩。

研究方向：药物创新的生态系统。

论文题目

药物创新在肿瘤治疗中的应用

Rethinking medical innovation for cancer management

1

作者简介：

打开网易新闻 查看更多图片

徐应永

Yingyong Xu

SJTU-UoM DBA 2017级

杭州启函生物科技有限公司 首席医学官CMO

上海交通大学医学院血液肿瘤学硕士，主要专注于抗肿瘤药物的临床开发与应用。曾在安徽省立医院和上海儿童医学中心从事儿童血液肿瘤的临床治疗。2011年进入制药行业，先后在百时美施贵宝和再鼎医药从事抗肿瘤药物的临床开发工作。2024年初加入启函生物。

2

论文摘要

本论文为癌症管理中的医疗创新提供了新的视角，丰富了理论文献，并为原创药物（FIC）的开发提供了启示。论文由三篇相互关联的研究论文组成，采用期刊格式以便发表。第一项研究旨在阐明影响癌症管理医疗创新新兴发展的驱动因素。我们的研究结果表明，癌症仍然是一个“persistent anomaly”。癌症研究和创新引入了诸多新范式，以首创药物为代表，针对疾病的不同方面进行治疗。这些进展使得新的治疗轨迹得以建立，并与既定和不断改善的实践相结合。第二项研究探讨了代表新范式的首创药物是如何出现的。该研究基于对参与首创药物创新的科学家、临床医生、管理者和投资者的访谈，为生态系统文献做出了贡献，强调了创新生态系统的关键作用。它突出了创新过程的动态特性及其在不同子生态系统安排中的表现。此外，我们的研究结果识别出在推动首创药物开发中至关重要的关键个人，这引出了第三项研究，考察这些关键个人在首创药物创新生态系统中作为创新倡导者的角色和活动。该论文对参与首创药物创新的政策制定者和专业人士具有实际意义。总之，首个研究为我们的整体研究建立了理论框架，而后两项研究则探讨了首创药物创新的具体细节。这些研究为管理突破性创新提供了实用见解，并可能适用于更广泛的突破性创新领域。

3

导师信息：

Dimitri Gagliardi

Senior Lecturer of UoM, IMP Innovation, Strategy and Sustainability

WAN Guohua

Professor of Management Science， ACEM SJTU

4

论文发表信息：

Xu, Y., & Gagliardi, D. (2023). Cancer research and innovation: conceptualising a persistent anomaly. Innovation: Organisation & Management. https://doi.org/10.1080/14479338.2023.2204322

5

Abstract：

This DBA thesis offers novel insights to the understanding of medical innovations in cancer management, thereby enriching the theoretical literature and offering implications for the development of first-in-class (FIC) drugs. The thesis is structured as three interrelated research papers formatted in a journal style for publication. The first study seeks to elucidate the drivers influencing new and emerging developments in medical innovation for cancer management. Our finding indicates that cancer continues to be a 'persistent anomaly.', cancer research and innovation have introduced several new paradigms, exemplified by FIC drugs, which target different facets of the disease. These developments have resulted in the establishment of new trajectories that have been integrated with established and improving practices. The second study investigates the emergence of FIC drugs that transform treatment paradigms. This study, which is based on interviews with scientists, clinicians, managers, and investors engaged in the innovation of FIC drugs, contributes to the literature on ecosystems by underscoring the essential role of innovation ecosystem. It highlights the dynamic nature of the innovation process and its manifestation across diverse sub-ecosystem arrangements. Furthermore, our findings identify key individuals who are critical in advancing FIC drug development, which leads to the third study that examines the roles and activities of these key individuals, who act as innovation champions within the FIC drug innovation ecosystem. The thesis has practical implications for policymakers and professionals involved in FIC drug innovation. In summary, the initial study establishes the theoretical framework for our research, while the following two studies explore the specifics of FIC drug innovation. These studies offer practical insights into managing radical innovation and may be applicable to the broader field of radical innovation.

咨询电话：021-52301020

阅读更多

  4. 打开网易新闻 查看更多图片

    关注“交大安泰高管教育”